TY - JOUR
T1 - Circulating interleukin-6 levels and incident ischemic stroke
AU - Papadopoulos, Andreas
AU - Palaiopanos, Konstantinos
AU - Björkbacka, Harry
AU - Peters, Annette
AU - de Lemos, James A.
AU - Seshadri, Sudha
AU - Dichgans, Martin
AU - Georgakis, Marios K.
N1 - Funding Information:
H. Björkbacka is supported by the Swedish Research Council and the Swedish Heart-Lung Foundation. The analysis from the Framingham Heart Study has been funded from NHLBI: HHSN 268201500001I and NINDS grant R01 NS017950 (S.S.). M. Dichgans is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198) and as part of CRC 1123 (B3) and DI 722/16-1. M. K. Georgakis is supported by a Walter-Benjamin fellowship from the German Research Foundation (DFG, GE 3461/1-1) and the FöFoLe program of LMU Munich (1120) and has received funding from the Onassis Foundation, the German Academic Exchang Service, and the Vascular Dmentia Research Foundation.
Funding Information:
H. Bj?rkbacka is supported by the Swedish Research Council and the Swedish Heart-Lung Foundation. The analysis from the Framingham Heart Study has been funded from NHLBI: HHSN 268201500001I and NINDS grant R01 NS017950 (S.S.). M. Dichgans is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany?s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy?ID 390857198) and as part of CRC 1123 (B3) and DI 722/16-1. M. K. Georgakis is supported by a Walter-Benjamin fellowship from the German Research Foundation (DFG, GE 3461/1-1) and the F?FoLe program of LMU Munich (1120) and has received funding from the Onassis Foundation, the German Academic Exchang Service, and the Vascular Dmentia Research Foundation.
Publisher Copyright:
Copyright © 2021 American Academy of Neurology.
PY - 2022/3/8
Y1 - 2022/3/8
N2 - Background and Objectives Human genetic studies support a key role of interleukin-6 (IL-6) in the pathogenesis of ischemic stroke. However, there are only limited data from observational studies exploring circulating IL-6 levels as a risk factor for ischemic stroke. We set out to perform a systematic review and meta-analysis of aggregate data on cohort studies to determine the magnitude and shape of the association between circulating IL-6 levels and risk of incident ischemic stroke in the general population. Methods Following the PRISMA guidelines, we systematically screened the PubMed search engine from inception to March 2021 for population-based prospective cohort studies exploring the association between circulating IL-6 levels and risk of incident ischemic stroke. We pooled association estimates for ischemic stroke risk with random-effects models and explored nonlinear effects in dose–response meta-analyses. Risk of bias was assessed with the Newcastle-Ottawa Scale (NOS). We used funnel plots and trim-to-fill analyses to assess publication bias. Results We identified 11 studies (n = 27,411 individuals; 2,669 stroke events) meeting our eligibility criteria. Mean age of all included participants was 60.5 years and 54.8% were female. Overall, quality of the included studies was high (median 8 out of 9 NOS points, interquartile range 7–9). In meta-analyses, 1 SD increment in circulating log-transformed IL-6 levels was associated with a 19% increase in risk of incident ischemic stroke over a mean follow-up of 12.4 years (relative risk 1.19; 95% confidence interval 1.10 to 1.28). A dose–response meta-analysis showed a linear association between circulating IL-6 levels and ischemic stroke risk. There was only moderate heterogeneity and the results were consistent in sensitivity analyses restricted to studies of low risk of bias and studies fully adjusting for demographic and vascular risk factors. The results also remained stable following adjustment for publication bias. Discussion Higher circulating IL-6 levels in community-dwelling individuals are associated with higher long-term risk of incident ischemic stroke in a linear pattern and independently of conventional vascular risk factors. Along with findings from genetic studies and clinical trials, these results provide additional support for a key role of IL-6 signaling in ischemic stroke.
AB - Background and Objectives Human genetic studies support a key role of interleukin-6 (IL-6) in the pathogenesis of ischemic stroke. However, there are only limited data from observational studies exploring circulating IL-6 levels as a risk factor for ischemic stroke. We set out to perform a systematic review and meta-analysis of aggregate data on cohort studies to determine the magnitude and shape of the association between circulating IL-6 levels and risk of incident ischemic stroke in the general population. Methods Following the PRISMA guidelines, we systematically screened the PubMed search engine from inception to March 2021 for population-based prospective cohort studies exploring the association between circulating IL-6 levels and risk of incident ischemic stroke. We pooled association estimates for ischemic stroke risk with random-effects models and explored nonlinear effects in dose–response meta-analyses. Risk of bias was assessed with the Newcastle-Ottawa Scale (NOS). We used funnel plots and trim-to-fill analyses to assess publication bias. Results We identified 11 studies (n = 27,411 individuals; 2,669 stroke events) meeting our eligibility criteria. Mean age of all included participants was 60.5 years and 54.8% were female. Overall, quality of the included studies was high (median 8 out of 9 NOS points, interquartile range 7–9). In meta-analyses, 1 SD increment in circulating log-transformed IL-6 levels was associated with a 19% increase in risk of incident ischemic stroke over a mean follow-up of 12.4 years (relative risk 1.19; 95% confidence interval 1.10 to 1.28). A dose–response meta-analysis showed a linear association between circulating IL-6 levels and ischemic stroke risk. There was only moderate heterogeneity and the results were consistent in sensitivity analyses restricted to studies of low risk of bias and studies fully adjusting for demographic and vascular risk factors. The results also remained stable following adjustment for publication bias. Discussion Higher circulating IL-6 levels in community-dwelling individuals are associated with higher long-term risk of incident ischemic stroke in a linear pattern and independently of conventional vascular risk factors. Along with findings from genetic studies and clinical trials, these results provide additional support for a key role of IL-6 signaling in ischemic stroke.
UR - http://www.scopus.com/inward/record.url?scp=85125964268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125964268&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000013274
DO - 10.1212/WNL.0000000000013274
M3 - Article
C2 - 34969940
AN - SCOPUS:85125964268
SN - 0028-3878
VL - 98
SP - E1002-E1012
JO - Neurology
JF - Neurology
IS - 10
ER -